Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle
- Authors
- Kim, Jin Kyeoung; Choi, Kyung-Ju; Lee, Minhyung; Jo, Mi-hee; Kim, Soonhag
- Issue Date
- Jan-2012
- Publisher
- Elsevier Science Inc.
- Keywords
- Aptamer; microRNA-221; Theragnostics; Molecular beacon; Multimodal nanoparticles; Cancer targeting
- Citation
- Biomaterials, v.33, no.1, pp 207 - 217
- Pages
- 11
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Biomaterials
- Volume
- 33
- Number
- 1
- Start Page
- 207
- End Page
- 217
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/166479
- DOI
- 10.1016/j.biomaterials.2011.09.023
- ISSN
- 0142-9612
1878-5905
- Abstract
- MicroRNAs (miRNA, miR) have been reported as cancer biomarkers that regulate tumor suppressor genes. Hence, simultaneous detecting and inhibiting of miRNA function will be useful as a cancer theragnostics probe to minimize side effects and invasiveness. In this study, we developed a cancer-targeting therangostics probe in a single system using an AS1411 aptamer - and miRNA-221 molecular beacon (miR-221 MB)-conjugated magnetic fluorescence (MF) nanoparticle (MFAS miR-221 MB) to simultaneously target to cancer tissue, image intracellularly expressed miRNA-221 and treat miRNA-221-involved carcinogenesis. AS1411 aptamer-conjugated MF (MFAS) nanoparticles displayed a great selectivity and delivery into various cancer cell lines. The miR-221 MB detached from the MFAS miR-221 MB in the cytoplasm of C6 cells clearly imaged miRNA-221 biogenesis and simultaneously resulted in antitumor therapeutic effects by inhibiting miRNA function, indicating a successful astrocytoma-targeting theragnostics. MFAS miRNA MB can be easily applied to other cancers by simply changing a targeted miRNA highly expressed in cancers.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.